(EMAILWIRE.COM, November 27, 2018 ) Global Cancer Drug Industry was valued at USD 73.40 Billion in the year 2017. Global Cancer Drug Industry is further estimated to grow at a CAGR of 7.98% from 2018 to 2025 to reach USD 135.71 Billion by the year 2025. North America region holds the highest Industry share in 2017 with APAC region is considered as the fastest growing Industry in the forecasted period. At a country level, the U.S is the biggest Industry in 2017 and it is projected to grow at a gradual pace in the coming years.
The major market players in Cancer Drug Industry are Roche Holdings Inc., Johnson & Johnson, Novartis AG, Celgene, Eli Lilly and Company, Pfizer, Celgene Corporation, Sanofi, Merck & Co., Amgen Inc. (Other 13 companies detailed information is provided in research report). Roche Diagnostics holds the substantial Industry share because of its better global presence both at production and at an operational level. Rising research and development expenses to cater changing demand of end users, similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years.
Get Free Sample Report@ http://www.qurateresearch.com/report/sample/HnM/QBI-GRS-HnM-116231
SWOT Analysis of Cancer Drugs Industry
Strength
Growing incidence and pervasiveness of various types of cancer
Academic alliances and partnerships
Weakness
Side-effects of anti-cancer drug therapy
The high cost of drug development and a threat of failure
Opportunity
Scientific advancements in treatment methods
Increasing focus on personalized Anti-cancer medicine
Threats
Patent Cliff
The Immunotherapy segment in the global Cancer Drug Industry is expected to hold the highest Industry share during the forecast period. The growth can be attributed to growing areas within oncology R&D, high efficacy and fewer side effects and unique molecular level targeting. On the other hand, Blood Cancer by the application is expected to grow at the highest CAGR during the year 2018-2025. Majorly due to growing number of blood cancer patient and the high cost of drugs used for the treatment of blood cancer.
Enquiry about Report@ http://www.qurateresearch.com/report/enquiry/HnM/QBI-GRS-HnM-116231
By Application
Gastrointestinal cancer
Blood cancer
Prostate cancer
Skin cancer
Respiratory/lung cancer
Breast cancer
Other types of cancers
By Products & Services
Immunotherapy (biologics therapy)
Hormonal therapy
Targeted therapy
Chemotherapy
Others
Purchase Report@ http://www.qurateresearch.com/report/buy/HnM/QBI-GRS-HnM-116231/
By Region
North America
USA
Canada
Europe
Germany
U.K.
France
Italy
Rest of Europe
APAC
China
India
Japan
Rest of Asia-Pacific
RoW
Latin America
Middle East & Africa
Nehal Chinoy
+919881074592
nehal@qurateresearch.com
Source: EmailWire.Com 
